Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07314164) titled 'Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment' on Dec. 18, 2025.
Study Type: Observational
Primary Sponsor: Ipsen
Condition:
Neuroendocrine Tumors
Recruitment Status: Not recruiting
Date of First Enrollment: December 31, 2025
Target Sample Size: 150
To know more, visit https://clinicaltrials.gov/study/NCT07314164
Published by HT Digital Content Services with permission from Health Daily Digest....